NCT00343915 - Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs | Biotech Hunter

Enrollment

267

Participants

Timeline

Start Date

April 21, 2004

Primary Completion Date

January 10, 2008

Study Completion Date

January 10, 2008

Conditions

Hepatitis B

Interventions

BIOLOGICAL

Engerix™-B (thiomersal-free) 20µg

In the primary study: 2 deep intramuscular injections (Months 0, \& 6)

BIOLOGICAL

10 μg Engerix™-B (preservative-free)

In the primary study: 3 deep intramuscular injections (months 0, 1 \& 6)

BIOLOGICAL

placebo

In the primary study: 1 deep intramuscular injection (month 1)

Trial Locations (4)

GSK Investigational Site, Brussels

GSK Investigational Site, Wilrijk

GSK Investigational Site, Sydney

GSK Investigational Site, Kyiv